Search
The U.S. FDA Approves First AI Tool to Accelerate Drug Development for Liver Diseases
2025-12-09 /
Read about 0 minute
Author：小编
The U.S. Food and Drug Administration (FDA) announced on Monday that it has approved the first artificial intelligence-based drug development tool—the Artificial Intelligence-based Non-Alcoholic Steatohepatitis Histological Measurement Tool (AIM-NASH). This tool is designed to assist doctors in evaluating severe fatty liver disease during drug trials and can be used in any eligible drug development project.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
